CYTK insider trade: 2,105 shares sold after option exercise

Rhea-AI Filing Summary

Cytokinetics (CYTK) disclosed a Form 4 for its EVP of Research & Development reporting insider transactions on 10/21/2025. The officer exercised 2,105 non-derivative shares via an option at $10.60 per share (code M) and sold 2,105 shares at $58.22 (code S) on the same date. Following these transactions, the reporting person directly holds 140,610 shares of common stock. A non-qualified stock option with an exercise price of $10.60, initially exercisable on 03/28/2017 and expiring on 02/28/2027, shows 1,000 derivative securities beneficially owned after the reported activity.

Insights

Insider transactions analyst

Neutral Form 4: small option exercise and matched sale.

The filing lists an option exercise (code M) of 2,105 shares at $10.60 and a same-day sale (code S) of 2,105 shares at $58.22 on 10/21/2025. The transactions are routine and limited in size.

Post-transaction direct ownership is 140,610 common shares. The derivative table shows 1,000 options remaining with a $10.60 strike, exercisable since 03/28/2017 and expiring on 02/28/2027. Actual market impact depends on trading volume and holder decisions.

Insider Trade Summary

Exercise and Sale: 2,105 shares ($100K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Malik Fady Ibraham

Role EVP Research & Development

Sold 2,105 shs ($123K)

Approx. gross sale proceeds $123K

Approx. exercise cost $22K

Approx. pre-tax spread $100K

Type	Security	Shares	Price	Value
Exercise	Non-Qualified Stock Option (Right to Buy)	2,105	$0.00	$0.00
Exercise	Common Stock	2,105	$10.60	$22K
Sale	Common Stock	2,105	$58.22	$123K

Holdings After Transaction: Non-Qualified Stock Option (Right to Buy) — 1,000 shares (Direct); Common Stock — 140,610 shares (Direct)

FAQ

What insider activity did CYTK report in this Form 4?

An officer exercised 2,105 options at $10.60 and sold 2,105 common shares at $58.22 on 10/21/2025.

Who is the reporting person in the CYTK Form 4?

An Officer of Cytokinetics serving as EVP Research & Development.

How many CYTK shares does the insider hold after the transactions?

The reporting person directly owns 140,610 common shares following the reported transactions.

What options remain for the CYTK insider after these trades?

A non-qualified stock option with 1,000 derivative securities remains, strike $10.60, expiring 02/28/2027.

What were the transaction codes used in the CYTK Form 4?

Code M for option exercise and code S for an open market sale.

On what date did the CYTK insider transactions occur?

The transactions occurred on 10/21/2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 10/21/2025 - 06:18 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Malik Fady Ibraham

(Last) (First) (Middle)

350 OYSTER POINT BLVD

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CYTOKINETICS INC [ CYTK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP Research & Development

3. Date of Earliest Transaction (Month/Day/Year)
10/21/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/21/2025		M		2,105	A	$10.6	142,715	D
Common Stock	10/21/2025		S		2,105	D	$58.22	140,610	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualified Stock Option (Right to Buy)	$10.6	10/21/2025		M			2,105	03/28/2017	02/28/2027	Common Stock	2,105	$0	1,000	D

Explanation of Responses:

	/s/ John O. Faurescu, attorney-in-fact for Dr. Malik	10/21/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.